Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has plans to ensure that pancreatic enzyme replacement therapy is made a UK-wide priority in pancreatic cancer care.
The National Institute for Health and Care Excellence’s guidelines recommend that pancreatic enzyme replacement therapy (PERT) should be considered for people with both operable and inoperable pancreatic cancer. The National Health Service has commissioned an audit into pancreatic cancer so that wider improvements can be made for patients and any variations in treatment, including access to PERT, can be reduced.